Table 1. Baseline Characteristics of Included Studies.
Authors and published years | Data collection | Pts No | Country of origin | Ethnicity | pCR definition | Cut-off value | Assay | Marker | Time | Location | Neoadjuvant regimen |
Ladoire et al. 2008 [27] | Retrospective | 56 | France | Europe | ypT0 | Scores>0 | IHC | CD3, CD8, FOXP3 | Pre-,post-NAC | IS | CEF,CEX, H,,DC |
Aruga et al. 2009 [24] | Retrospective | 87 | Japan | Asia | Japanese criteria | Median | IHC | FOXP3 | Pre-,post-NAC | IS | CEF,EC,EC-T,CEF-T |
Denkert et al. 2010a [25] | Prospective | 218 | Germany | Europe | ypT0/TisypN0 | 10%,LPBC,10% INC | H&E | TILs | Pre-NAC | IS,SS | EC-T |
Denkert et al. 2010b [25] | Prospective | 840 | Germany | Europe | ypT0/TisypN0 | 10%,LPBC,10% INC | H&E, IHC | TILs, CD3 | Pre-NAC | IS,SS | TAC, NX |
West et al. 2011 [33] | Prospective | 113 | Europe | Europe | Not clear | upper quartile | Gene-signature | TILs | Pre-NAC | BS | CEF,TET |
Oda et al. 2012 [30] | Retrospective | 180 | Japan | Asia | ypT0 ypN0 | median | IHC | CD8, FOXP3 | Pre-,post-NAC | IS | CEF-T |
Ono et al. 2012 [31] | Retrospective | 180 | Japan | Asia | ypT0 | score>2 | H&E | TILs | Pre-NAC | BS | AC,ACT,CEF,AT, CEF-T |
Yamaguchi et al. 2012 [34] | Retrospective | 68 | Japan | Asia | ypT0 | Score>1 | H&E | TILs | Pre-NAC | BS | CEF-T |
Liu et al. 2012 [28] | Retrospective | 132 | China | Asia | ypT0 | median | IHC | FOXP3 | Pre-,post-NAC | SS | CEF,CEX |
Seo et al. 2013 [32] | Retrospective | 153 | Korea | Asia | ypT0 ypN0 | median | IHC | CD4,CD8, FOXP3 | Pre-NAC | IS | AC,AC-T,AD |
Lee et al. 2013 [42] | Retrospective | 175 | Korea | Asia | ypT0 ypN0 | 10%,10% INC | IHC | CD3,CD8,FOXP3 | Pre-NAC | SS | AT,AC-T,H |
Loi et al. 2013 [43] | Retrospective | 156 | Germany | Europe | ypT0, ypTis | 10% INC | H&E | TILs | Pre- NAC | SS | EC-TX, H,EC-T |
Denkert et al. 2013 [41] | Prospective | 580 | Germany | Europe | ypT0ypN0 | LPBC,10% INC, | H&E | TILs | Pre-NAC | IS,SS | PM+/−Cb,Bev,H,L |
Issa-Nummer et al. 2013 [26] | Prospective | 313 | Germany,Switzerland | Europe | ypT0ypN0 | 10% INC | H&E | TILs | Pre- NAC | IS,SS | EC-T,Bev,EVE, L |
Abbreviations: pts, patients; IHC, immunohistochemistry; HE, staining Hematoxylin-eosin staining; FOXP3, regulatory T-lymphocytes expressing forkhead box P 3 protein; NAC, neoadjuvant chemotherapy; CEF, cyclophosphamide/epirubicin/fluorouracil; CEX, epirubicin/cyclophosphamide/capecitabine; DC, docetaxel/carboplatin; EC, epirubicin/cyclophosphamide; EC-T, epirubicin/cyclophosphamide-taxane; CEF-T, cyclophosphamide/epirubicin/fluorouracil-taxane;T AC, docetaxel/doxorubicin/cyclophosphamide; NX, vinorelbine/capecitabine; TET, docetaxel-docetaxel/epirubicin; AC, doxorubicin/cyclophosphamide; AC-T, doxorubicin/cyclophosphamide-taxane; AD, doxorubicin/docetaxel; AT, doxorubicin/taxane; EC-TX, epirubicin/cyclophosphamide-docetaxel/capecitabine; EC-T-X, epirubicin/cyclophosphamide-docetaxel-capecitabine; PM, paclitaxle/non-pegylated liposomal doxorubicin; PMCb, paclitaxle/non-pegylated liposomal doxorubicin/carboplatin; H, trastuzumab; Bev, bevacizumab; L, lapatinib; EVE, everolimus; IS = Intratumoral sites; SS = stromal sites;BS, both sites;10% INC, 10 increment
a, GeparDuo.
b, GeparTrio.